Final answer:
The correct agent to correct coagulopathy in uremic patients is Desmopressin (DDAVP). It acts by increasing the activity of factor VIII and release of von Willebrand factor, helping to mitigate the bleeding tendency associated with uremia.
Step-by-step explanation:
The agent used to correct coagulopathy in uremic patients is Desmopressin (DDAVP). Desmopressin is a synthetic analogue of the natural antidiuretic hormone vasopressin and is used in the treatment of uremic bleeding. It acts by releasing the von Willebrand factor and increasing factor VIII activity, which are necessary for the clotting process. Uremic patients often have impaired platelet function, leading to a bleeding tendency that can be ameliorated with Desmopressin. This treatment does not involve the supply of red blood cells, plasma proteins, or megakaryocytes but affects the function of existing platelets and enhances the action of specific blood clotting factors. Fresh frozen plasma (FFP) is also used but less specific, while vitamin K is generally used for deficiencies related to clotting factor synthesis and Factor VIIa is used in certain bleeding disorders but not specifically for uremic coagulopathy.